Clinical trials: Neoplasm Circulating Cells
Colorectal Cancer
Tumoral Circulating Cells and Colorectal Cancer Progression
Prospective research of circulating tumor cells as markers of progression risk in colorectal cancer.
- Trial name
- NCT03256084
- Testing
- Blood and tumor samples
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Paoli-Calmettes
Prostate Cancer Metastatic
Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer
As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed.
- Trial name
- NCT03089099
- Testing
- Blood drawing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Breast Cancer, Breast Cancer Female
Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
A central challenge in the fight against breast cancer is how to detect disease in a noninvasive manner before it is detectable by imaging methods.
- Trial name
- NCT03480659
- Where
- Kazakhstan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- HKGepitherapeutics
Circulating Tumor Cells, CTC
CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System
Despite the growing public awareness and recent progress in multimodality therapy to the colorectal cancer (CRC), CRC still ranks high on the list of the most common and deadly cancers in Taiwan.
- Trial name
- NCT03013868
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Lymphoma
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone…
- Trial name
- NCT04980222
- Testing
- Glofitamab, Tocilizumab, Doxorubicin
- Where
- 20 sites in United States, Denmark and 4 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma, Circulating Platelet-monocyte Conjugates
Glioblastoma Platelet Activation Study
Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.
- Trial name
- GPAS (NCT02887417)
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma
Study of DNA in Blood Samples From Patients With Neuroblastoma
This research trial studies is deoxyribonucleic acid (DNA) in blood samples from patients with neuroblastoma. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that…
- Conditions
- Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma
- Trial name
- NCT00898391
- Testing
- laboratory biomarker analysis, polymerase chain reaction, polyacrylamide gel electrophoresis
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- Children's Oncology Group
Locally Advanced Breast Cancer, Circulating Tumor Cell
CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in neoadjuvant chemotherapy among locally…
- Trial name
- CTCNeoBC (NCT03732339)
- Testing
- GILUPI CellCollector®
- Where
- China
- Volunteers
- 29 people
- Sponsor
- RenJi Hospital
Small Cell Lung Cancer Extensive Stage
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and…
- Trial name
- NCT05066945
- Testing
- Observation
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Lymphoma, Lymphoma, B-Cell
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06693830
- Testing
- Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Hua-Jay J Cherng, MD
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
Cancer Panel From Blood of Lung Cancer Patients
Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making.
- Trial name
- CAPABLE (NCT03235765)
- Testing
- MACROGEN Pan Cancer Panel (Tier 2)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Resectable Esophageal Cancer
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer
Despite the availability of several preoperative diagnostic techniques, accurate pretreatment staging of esophageal cancer (EC) remains challenging.
- Trial name
- NCT01858805
- Testing
- esophagectomy
- Where
- Germany
- Volunteers
- 123 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Neoplastic Cells, Circulating
The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in colorectal cancer could play an important role in…
- Trial name
- NCT02450422
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Esophageal Cancer
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with…
- Trial name
- MRD2START (NCT06914011)
- Testing
- Tislelizumab
- Volunteers
- 172 people
- Sponsor
- Asan Medical Center
Colorectal Cancer Metastatic
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab.
- Trial name
- Toco-CoR (NCT04245865)
- Testing
- Fluorouracil, Calcium folinate, Oxaliplatin
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- Vejle Hospital
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Prostate Cancer
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity
This clinical study is conducted to develop a new test to identify prostate cancer patients at highest risk of radiotherapy-related complications, especially related to gastrolintestinal (GI) toxicities.
- Trial name
- NCT04580667
- Testing
- Collection of plasma samples
- Where
- 5 sites in United States
- Sponsor
- DiaCarta, Inc.
Breast Cancer, Ovarian Cancer
Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System
The study evaluates the level and molecular profiles of different CTC populations as markers for predicting the risk of developing hematogenous metastases and the effectiveness of treatment in patients with tumors of the female…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- CTCs (NCT04817501)
- Testing
- Taking 5 ml of venous blood at different time intervals, Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
- Where
- Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Lymphoma
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study
The next-generation sequencing (NGS) based on liquid biopsy has been an emerging technology to identify tumor-specific genetic aberrations in malignant tumors.
- Trial name
- NCT04957901
- Testing
- Pediatric lymphoma protocol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University